|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2000-10-16
|
|
pubmed:abstractText |
PURPOSE; The aim of this study was to investigate the toxicity and efficacy of a more convenient topotecan administration schedule (in contrast to the "standard" 1.5 mg/m(2)/day x 5 days q 21 days) in the management of platinum- and paclitaxel-refractory ovarian cancer.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0090-8258
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright 2000 Academic Press.
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
79
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
116-9
|
|
pubmed:dateRevised |
2004-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:11006042-Adult,
pubmed-meshheading:11006042-Aged,
pubmed-meshheading:11006042-Aged, 80 and over,
pubmed-meshheading:11006042-Antineoplastic Agents,
pubmed-meshheading:11006042-Antineoplastic Agents, Phytogenic,
pubmed-meshheading:11006042-CA-125 Antigen,
pubmed-meshheading:11006042-Carboplatin,
pubmed-meshheading:11006042-Cisplatin,
pubmed-meshheading:11006042-Drug Administration Schedule,
pubmed-meshheading:11006042-Drug Resistance, Neoplasm,
pubmed-meshheading:11006042-Fallopian Tube Neoplasms,
pubmed-meshheading:11006042-Female,
pubmed-meshheading:11006042-Humans,
pubmed-meshheading:11006042-Middle Aged,
pubmed-meshheading:11006042-Ovarian Neoplasms,
pubmed-meshheading:11006042-Paclitaxel,
pubmed-meshheading:11006042-Peritoneal Neoplasms,
pubmed-meshheading:11006042-Topotecan
|
|
pubmed:year |
2000
|
|
pubmed:articleTitle |
Phase 2 evaluation of topotecan administered on a 3-day schedule in the treatment of platinum- and paclitaxel-refractory ovarian cancer.
|
|
pubmed:affiliation |
Gynecologic Cancer Program, The Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio 44195, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Clinical Trial, Phase II
|
